CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
巴西血液学、血液疗法与细胞治疗协会关于基因修饰细胞的共识。VIII：CAR-T 细胞的临床前开发——安全性与疗效评价
英文原题：Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation.
查看英文原题
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
目前，市场上有四种CAR-T 产品可供商业使用。CAR-T 细胞已显示出高缓解率，它们代表了耐药或难治性B细胞恶性肿瘤患者的一种有效治疗选择。这些细胞治疗产品的批准是在经过长时间的临床前评估之后获得的，这些评估在这一难以治疗的患者群体中展示了前所未有的疗效。这篇综述文章概述了CAR-T 细胞产品开发所需的主要临床前评估。
展开英文摘要原文
Currently, there are four CAR-T products commercially available on the market. CAR-T cells have shown high remission rates and they represent an effective treatment option for patients with resistant or refractory B cell malignancies. Approval of these cell therapy products came after an extended period of preclinical evaluation that demonstrated unprecedented efficacy in this difficult-to-treat patient population. This review article outlines the main preclinical evaluations needed for CAR T cell product development.
论文信息
- 作者
- Picanço-Castro V、Bonamino MH、Ramos RN、Guerino-Cunha RL、Oliveira TGM、Rego EM
- 第一作者单位
- Fundação Hemocentro de Ribeirão Preto, Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, (HC FMRPUSP) Ribeirão Preto, SP, Brazil.Brazil
- 通讯作者单位
- Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto (HCFMRP USP), Ribeirão Preto, SP, Brazil. Electronic address: emrego@hcrp.fmrp.usp.br.Brazil
- 期刊
- Hematology, transfusion and cell therapy2021 Nov
- 原文标识
- PubMed 34794798 · DOI 10.1016/j.htct.2021.09.008
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →